Clients say that he is a “pharmaceuticals sector expert.”The Legal 500 2018

Robbie McLaren

  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom

Robbie McLaren is a partner in the London office of Latham & Watkins and Co-Chair of the London Corporate Department. His practice focuses primarily on cross-border M&A, joint ventures, venture capital, reorganizations, and general corporate matters. Mr. McLaren has represented clients who operate in a number of industries, with a particular focus on clients in the life sciences, healthcare, and technology industries.

Mr. McLaren is the editor of the newly published Carve-out M&A Transactions: A Practical Guide.

Mr. McLaren's representative experience includes advising:

Life Sciences and Healthcare

  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with the US$703 million acquisition by CVC Capital Partners of women’s healthcare assets from Teva Pharmaceutical Industries Ltd.
  • Abcam plc, a global life sciences company, in regards to its license and asset purchase agreement with Roche Tissue Diagnostics to obtain exclusive rights to the product portfolio of Spring Bioscience Corporation (Spring)
  • Baxter International Inc., in connection with its US$625 million acquisition of Claris Injectables Limited, an India-based manufacturer of sterile injectables
  • Sienna Biopharmaceuticals in connection with its acquisition of Creabilis plc, a privately held specialty pharmaceutical company
  • Allergan on its US$40.5 billion sale of its global generics pharmaceuticals business to Teva
  • Certain investors on their financings of Entasis Therapeutics, Meira GTx, and Adaptimmune
  • The shareholders of Pharmathen SA, a Greek pharmaceuticals company, on their sale of a controlling interest in Pharmathen to BC Partners
  • Actavis on its £306 million acquisition of Auden Mckenzie, a pharmaceutical company specializing in the development, licensing, and marketing of generic medicines and proprietary brands
  • Zogenix on its acquisition of Brabant Pharma, a UK-based pharmaceutical company
  • Actavis on the divestment of part of its Western European generics sale and marketing business to Aurobindo
  • Novo A/S on its £230 million disposal of Archimedes and its US$706 million acquisition of Xellia
  • Watson Pharmaceuticals on its €4.25 billion acquisition of the Actavis Group, making Watson the third largest global generics company

Technology, Media, and Telecoms

  • Telenor on its €2.8 billion sale of its assets in Central and Eastern Europe (CEE) to PPF Group
  • Kite Tech, a UK-based mobile e-commerce platform specializing in personalized print on its sale to Canon Europa
  • Netflix Inc. on the acquisition of Millarworld, a comic book company founded by Mark Millar
  • An Asian investor in connection with its investment in a major music and audio platform
  • Andreessen Horowitz on its minority investment in Improbable World Limited, a UK-based software developer focused on virtual and simulated worlds


  • Mubadala on the US$15 billion merger of EMAL and DUBAL to form Emirates Global Aluminium
  • Amphenol Corp on its US$1.28 billion acquisition of FCI Asia, a provider of interconnect solutions for the telecom, datacom, wireless communications, and industrial markets owned by Bain Capital
  • Solway Investment Group in connection with its sale of Rudnik SASA Makedonska Kamenica, a Macedonia-based mining field engaged in production of lead-zinc metal, to Orion Mine Finance Group and Fusion Capital
  • Norsk Hydro ASA on its US$5.27 billion acquisition of the majority of the aluminium business of Vale SA in Brazil and on its acquisition of an aluminium smelter in Iceland and two metal supplying companies in Holland and Sweden from Rio Tinto
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.